6-ethoxycarbonyl-7-hydroxythieno<3,2-b>pyridin-5(4H)-one | 74695-36-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 6-ethoxycarbonyl-7-hydroxythieno<3,2-b>pyridin-5(4H)-one
• 英文别名: 7-hydroxy-5-oxo-4,5-dihydro-thieno[3,2-b]pyridine-6-carboxylic acid ethyl ester；ethyl 7-hydroxy-5-oxo-4,5-dihydrothieno[3,2-b]pyridine-6-carboxylate；6-ethoxycarbonyl-7-hydroxy-thieno[3,2-b]pyridin-5(4H)-one；6-ethoxycarbonyl-7-hydroxythieno[3,2-b]pyridin-5(4H)-one；Ethyl 5,7-dihydroxythieno[3,2-b]pyridine-6-carboxylate；ethyl 7-hydroxy-5-oxo-4H-thieno[3,2-b]pyridine-6-carboxylate
• CAS: 74695-36-6
• 化学式: C₁₀H₉NO₄S
• 分子量: 239.252
• InChiKey: KQUKPJJTYCSWNH-UHFFFAOYSA-N

物化性质

• 熔点：
  212-213 °C(Solv: acetic acid (64-19-7); water (7732-18-5))
• 沸点：
  475.7±45.0 °C(Predicted)
• 密度：
  1.507±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-ethoxycarbonyl-7-hydroxythieno<3,2-b>pyridin-5(4H)-one 以18%的产率得到
  参考文献：
  名称：

  BARKER, J. M.;HUDDLESTON, P. R.;KEENAN, G. J., J. CHEM. RES. MICROFICHE, 1982, N 6, 158

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氨其噻吩-2-甲酸乙酯 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 9.5h， 生成 6-ethoxycarbonyl-7-hydroxythieno<3,2-b>pyridin-5(4H)-one
  参考文献：
  名称：

  Barker, John M.; Huddleston, Patrick R.; Chadwick, Nigel, Journal of Chemical Research, Miniprint, 1980, # 1, p. 113 - 126

  摘要：

  DOI：

文献信息

• TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES
  申请人：Sircar Jagadish

  公开号：US20080139551A1

  公开（公告）日：2008-06-12

  treatment of a variety of disorders, including the treatment of pathological conditions associated with tumor necrosis factor alpha. The inhibitors of tumor necrosis factor alpha have the following structures: including stereoisomers, pharmaceutically acceptable salts, and solvates thereof, wherein substituents are as defined herein. Compositions containing an inhibitor of tumor necrosis factor alpha in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  治疗各种疾病，包括与肿瘤坏死因子α相关的病理条件的治疗。肿瘤坏死因子α的抑制剂具有以下结构：包括立体异构体、药用可接受的盐和溶剂，其中取代基如本文所定义。还提供了含有肿瘤坏死因子α抑制剂与药用可接受载体结合的组合物，以及使用方法。
• [EN] INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE FOR MANAGEMENT OF METABOLIC DISORDER<br/>[FR] INHIBITEURS DE LA PROTÉINE TYROSINE PHOSPHATASE DE FAIBLE POIDS MOLÉCULAIRE (LMPTP) UTILES POUR LA PRISE EN CHARGE DES TROUBLES MÉTABOLIQUES
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2022058896A1

  公开（公告）日：2022-03-24

  The present invention relates to novel modulators of low molecular weight protein tyrosine phosphatases and their use for the treatment of diseases or conditions mediated by LMPTP. Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, their safe pre-mixtures with polymers such as HPMC, HPMC-AS, Copovidone and methods for using such compounds, and pharmaceutical compositions containing them.

  本发明涉及新型低分子量蛋白酪氨酸磷酸酯酶的调节剂及其用于治疗由LMPTP介导的疾病或病症。此外，本发明还涉及制备这些化合物的过程，它们的互变异构体形式，其合成中所涉及的新型中间体，其药学上可接受的盐，其与聚合物（如HPMC，HPMC-AS，Copovidone）的安全预混物，以及使用这些化合物的方法和包含它们的药物组合物。
• Heteroaromatically condensed hydroxypyridonecarboxamides, their
  申请人：BASF Aktiengesellschaft

  公开号：US05593943A1

  公开（公告）日：1997-01-14

  Heteroaromatically condensed hydroxypyridonecarboxamides of the structure I ##STR1## where the substituents and the ring Q have the following meanings: R.sup.1 hydrogen, hydroxyl, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy; R.sup.2 hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, alkenyloxy, dialkylamino; or R.sup.1, R.sup.2 together denote an alkylene chain with 2-6 members and which may be interrupted by oxygen, sulfur or N-methyl; X oxygen or sulfur; Q a 5- or 6-membered heteroaromatic ring containing from 1 to 3 nitrogen atoms and/or one oxygen or sulfur atom as heteroatoms, and which may be substituted one to three times, and environmentally compatible salts thereof.

  化合物I的异芳基缩合羟基吡啶酮酰胺的结构如下：##STR1## 其中取代基和环Q具有以下含义：R.sup.1 氢、羟基、取代或未取代的烷基、烯基、炔基、环烷基、烷氧基；R.sup.2 氢、取代或未取代的烷基、烯基、炔基、环烷基、烯氧基、二烷基氨基；或R.sup.1、R.sup.2共同表示具有2-6个成员的烷基链，其中可以被氧、硫或N-甲基中断；X 氧或硫；Q为一个5-或6-成员的杂芳环，含有1-3个氮原子和/或一个氧或硫原子作为杂原子，可以被取代1-3次，并且其环境兼容盐。
• Thienopyridine derivatives
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US05219864A1

  公开（公告）日：1993-06-15

  Disclosed is a thienopyridine derivative represented by formula (I): ##STR1## wherein one of A and B represents --S-- and the other represents --CH.dbd.; R represents hydrogen or lower alkyl, and Z represents pyridyl; or a pharmaceutically acceptable salt thereof. The thienopyridine derivative is useful as an immunoregulator and for the prevention and treatment of osteoporosis.

  本发明公开了一种由式(I)所表示的噻吩并嘧啶衍生物：##STR1## 其中A和B中的一个表示--S--，另一个表示--CH.dbd.；R表示氢或低碳基，Z表示吡啶基；或其药学上可接受的盐。该噻吩并嘧啶衍生物可用作免疫调节剂，并用于预防和治疗骨质疏松症。
• Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
  申请人：Sircar Jagadish

  公开号：US20060229314A1

  公开（公告）日：2006-10-12

  Inhibitors of macrophage migration inhibitory factor having a thienopyridinone backbone are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with macrophage migration inhibitory factor activity. The inhibitors of macrophage migration inhibitory factor have the following structures: including forms such as stereoisomers, free forms, pharmaceutically acceptable salts or esters thereof, solvates, or combinations of such forms, wherein n, R 1 , R 2 , R 3 , X, and Y are as defined herein. Compositions comprising an inhibitor of macrophage migration inhibitory factor in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了具有噻吩并吡啶骨架的巨噬细胞迁移抑制因子抑制剂，其在治疗多种疾病中具有用途，包括治疗与巨噬细胞迁移抑制因子活性相关的病理条件。巨噬细胞迁移抑制因子的抑制剂具有以下结构：包括立体异构体、自由形态、药学上可接受的盐或酯、溶剂化物或这些形式的组合，其中n、R1、R2、R3、X和Y如本文所定义。还提供了包含巨噬细胞迁移抑制因子抑制剂与药学上可接受的载体组合的组合物，以及使用它们的方法。